Immatics Overview

  • Founded
  • 2000

Founded
  • Status
  • Public

  • Employees
  • 255

Employees
  • Stock Symbol
  • IMTX

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $7.92

  • (As of Friday Closing)

Immatics General Information

Description

Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.

Contact Information

Formerly Known As
Immatics Biotechnologies
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • Paul-Ehrlich-Strasse 15
  • 72076 Tubingen
  • Germany
+49 07071 00000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immatics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.92 $7.81 $5.75 - $13.60 $595M 76.2M 174K $0.57

Immatics Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 307,570 652,705 382,371
Revenue 163,277 41,100 35,626 20,653
EBITDA 45,776 (103,619) (237,077) (32,743)
Net Income 36,742 (110,350) (240,845) (35,342)
Total Assets 348,230 197,738 313,206 150,413
Total Debt 16,002 11,156 7,610 3,623
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Immatics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immatics‘s full profile, request access.

Request a free trial

Immatics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T c
Biotechnology
Tubingen, Germany
255 As of 2021
00000
000000000 00000

000000

commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit es
0000 000000000
Emeryville, CA
000 As of 0000
00000
000000000 00000

000000

Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliq
0000000000000
Hampton, NJ
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immatics Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gritstone bio Formerly VC-backed Emeryville, CA 000 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Hampton, NJ 000 00000 00000000 00000
0000 000000000000 Formerly VC-backed Houston, TX 00 00000 000000&0 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
You’re viewing 5 of 39 competitors. Get the full list »

Immatics Patents

Immatics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4113120-A1 Method of characterizing the binding characteristics between a peptide of interest and mhc molecules Pending 28-Jun-2021 00000000000
US-20230024554-A1 Method of characterizing the binding characteristics between a peptide of interest and mhc molecules Pending 28-Jun-2021 000000000000
US-20220356252-A1 Bma031 antigen binding polypeptides Pending 05-May-2021 00000000000
US-20220372165-A1 Antigen binding proteins specifically binding prame Pending 05-May-2021 000000000
US-20220283176-A1 Method for the absolute quantification of mhc molecules Pending 03-Mar-2021 G01N33/6842
To view Immatics’s complete patent history, request access »

Immatics Executive Team (22)

Name Title Board Seat Contact Info
Harpreet Singh Ph.D Board Member, Managing Directors, Chief Executive Officer & Co-Founder
Arnd Christ Chief Financial Officer, Finance
Steffen Walter Ph.D Chief Technology Officer, Technology
Toni Weinschenk Ph.D Co-Founder & Chief Innovation Officer
Rainer Kramer Ph.D Managing Director, Chief Business Officer & Site Head, Munich
You’re viewing 5 of 22 executive team members. Get the full list »

Immatics Board Members (15)

Name Representing Role Since
Adam Stone Self Board Member 000 0000
Eliot Forster Ph.D Self Board Member 000 0000
Friedrich von Bohlen und Halbach Ph.D dievini Board Member 000 0000
Heather Mason Self Board Member 000 0000
Michael Atieh Self Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Immatics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immatics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Immatics‘s full profile, request access.

Request a free trial

Immatics Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 31-Jul-2020 0000 000.00 Specialty Chemicals
ARYA Sciences Acquisition 01-Jul-2020 Merger/Acquisition Special Purpose Acquisition Company (SPAC) 00000000
To view Immatics’s complete investments and acquisitions history, request access »

Immatics ESG

Risk Overview

Risk Rating

Updated November, 22, 2022

27.54 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,613

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,004

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 462

Rank

00.00

Percentile

To view Immatics’s complete esg history, request access »